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Abstract
Aims/hypothesis A meta-analysis of 21 genome-wide asso-
ciation studies identified 11 novel genetic loci implicated in
fasting glucose homeostasis. We aimed to evaluate the
impact of these variants on insulin release and insulin
sensitivity estimated from OGTTs.
Methods Eleven variants in or near DGKB/TMEM195,
ADCY5, MADD, ADRA2A, FADS1, CRY2, SLC2A2, GLIS3,
PROX1, C2CD4B and IGF1 were genotyped in 6,784
middle-aged participants of the population-based Inter99
cohort. Association studies of quantitative estimates of
insulin release and insulin sensitivity were performed in
5,722 non-diabetic Danish participants on whom an OGTT
was performed.
Results Assuming an additive genetic model, carriers of the
alleles increasing fasting glucose in DGKB/TMEM195,
ADRA2A, GLIS3 and C2CD4B showed decreased glucose-
stimulated insulin release as assessed by the BIGTT-acute
insulin response index (2.7–3.5%; p<0.005 for all) and by
corrected insulin response (2.8–5.9%; p<0.03 for all). In
addition, the PROX1 glucose-raising allele showed a 2.9%
decreased corrected insulin response (p=0.03), while the
hyperglycaemic allele of variants in or near ADRA2A,
FADS1, CRY2 and C2CD4B were associated with a 2.6% to
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9.3% decrease in one or both of two different OGTT-based
disposition indices (p<0.02 for all). After correction for
multiple testing, variants in the DGKB/TMEM195,
ADRA2A, GLIS3 and C2CD4B loci were associated with
estimates of beta cell function.
Conclusions/interpretation We found that the lead variants
at the DGKB/TMEM195, ADRA2A, GLIS3 and C2CD4B
loci were associated with decreased glucose-stimulated
insulin response. This association underlines the importance
of pancreatic beta cell dysfunction in the genetic predispo-
sition to hyperglycaemia and type 2 diabetes.
Keywords Association study . Beta cell dysfunction .
Beta cell function . Genetic epidemiology . Glucose
homeostasis . Glucose-stimulated insulin release .
Type 2 diabetes
Abbreviations
AIR Acute insulin release
CIR Corrected insulin response
DI Disposition index
GWAS Genome-wide association study
HOMA-B HOMA of beta cell function
HOMA-IR HOMA of insulin resistance
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SNP Single nucleotide polymorphism
Introduction
For years it has been well known that genetic factors are
crucially important for the development of type 2 diabetes.
So far, genome-wide association studies (GWAS) and
subsequent meta-analysis have identified 23 validated risk
loci influencing risk of type 2 diabetes [1–3]. While many
common gene variants have shown an influence on
estimates of beta cell function, only few variants have an
impact on insulin resistance [2, 4–7].
Besides evidence from association analysis of dichoto-
mous phenotypes such as type 2 diabetes, novel knowledge
of the genetic complexity of glucose regulation and
homeostasis has come from GWAS of quantitative glycae-
mic traits. Hyperglycaemia in the fasting state is a major
criterion in the definition of type 2 diabetes [8]. Type 2
diabetes is a risk factor for development of cardiovascular
disease, but increased fasting glucose at non-diabetic levels
also increases risk of cardiovascular events [9]. Several loci
have been shown to influence this variable [10–17].
Recently, the international Meta-Analysis of Glucose and
Insulin-related Trait Consortium (MAGIC) collaboration
engaged in a large meta-analysis of data from 21 GWAS
and identified novel loci influencing fasting glucose
homeostasis. The initial discovery stage included 46,186
individuals. After replication in up to 76,558 individuals,
16 loci, ten of them novel, were found to be associated with
fasting plasma glucose and one novel locus with fasting
serum insulin at a genome-wide significant level [18].
Interestingly, variants at GCK, GCKR, DGKB/TMEM195,
ADCY5 and PROX1 loci showed novel association with
type 2 diabetes at a genome-wide significance level in
case–control studies of up to 127,677 individuals [18].
These five loci are thus part of the growing list of common
type 2 diabetes susceptibility loci [18]. Also, several
variants showed robust association with the HOMA index
of beta cell function (HOMA-B), a surrogate measure of
beta cell function in the fasting state.
While fasting levels of glucose and the derived
HOMA-B index may depict important processes in the
regulation of basal glycaemia, they are not informative
with regard to complex dynamic postprandial glucose
regulation [19, 20]. We therefore evaluated possible
associations with estimates of insulin release and insulin
sensitivity based on outcomes of OGTT, with a view to
further describing the relationship between these variants
and elements of glucose homeostasis. We investigated the
11 novel loci implicated in fasting glucose homeostasis in
5,722 non-diabetic individuals of the population-based
Inter99 study on whom an OGTT had been performed.
The remaining six loci have previously been investigated
in this population [10, 12, 21–23].
Methods
Participants The Inter99 cohort is a population-based,
randomised, non-pharmacological intervention study for
the prevention of ischaemic heart disease, conducted on
6,784 middle-aged participants at the Research Centre for
Prevention and Health in Glostrup, Copenhagen (Clinical-
Trials.gov: NCT00289237) [24]. An OGTT was performed
with measurement of plasma glucose and serum insulin at
fasting, and at 30 and 120 min after glucose intake.
Subsequently, 6,094 participants of Danish nationality and
with available DNA were classified as having normal
glucose tolerance (n=4,525), impaired fasting glycaemia
(n=504), impaired glucose tolerance (n=693), screen-
detected and treatment-naive diabetes (n=253), or previ-
ously diagnosed diabetes (n=119) according to WHO 1999
criteria [8]. The analysis of quantitative diabetes-related
phenotypes was performed in 5,722 non-diabetic partic-
ipants. Detailed characteristics of Inter99 are presented in
Table 1.
Informed written consent was obtained from all individ-
uals before participation. The study was approved by the
Ethical Committee of Copenhagen County and conducted
in accordance with the principles of the Helsinki Declara-
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tion II. Biochemical and anthropometric measures were
obtained as previously detailed [25].
Indices of insulin release and insulin sensitivity Oral
glucose-stimulated insulin release was reported as serum
insulin at 30 min during the OGTT, the BIGTT-acute
insulin response (AIR) index and the corrected insulin
response (CIR). Insulin sensitivity was reported as the
OGTT-derived BIGTT sensitivity index (SI). CIR was
calculated as: serum insulin30min pmol=lf g=6:945½   100ð Þ=
plasma glucose30min mmolfð =lg plasma glucose30min mmol=f½
lg  3:89Þ [26]. The BIGTT indices apply information on
sex and BMI, combined with plasma glucose and serum
insulin during an OGTT, to provide indices for AIR and SI,
and were calculated as reported [27]. In order to construct
OGTT-based disposition indices (DIs) we multiplied
BIGTT-AIR with BIGTT-SI (DI 1) and CIR with the
reciprocal of HOMA of insulin resistance (HOMA-IR)
(DI 2). The DI is an estimate of the ability of the pancreatic
beta cell to respond appropriately to concomitant levels of
insulin sensitivity.
Genotyping We genotyped 11 gene variants by KASPar
SNP Genotyping system (KBiosciences, Hoddesdon, UK).
All genotyping success rates were above 96% with a
mismatch rate below 0.5% in 591 pairs genotyped in
duplicate. The distribution of genotypes for all variants
were in Hardy–Weinberg equilibrium in Inter99 (p>0.05),
except for rs21911349 and rs11920090 (p=0.01 and p=
0.008, respectively).
Statistical analysis General linear statistical methodology
was used to test quantitative traits in relation to genotype,
applying additive models adjusting for the effect of age
(BIGTT-SI and BIGTT-AIR) or age and sex (all other
traits). Values of serum insulin and derived indices (except
BIGTT-SI) were logarithmically transformed prior to anal-
ysis. The multivariate method, Hotelling’s T2, was applied
to test the simultaneous effect of genotype on BIGTT-SI and
BIGTT-AIR. A p value of less than 0.05 was considered
significant. Correlation between quantitative metabolic
traits independent of genotype was performed by Pearson
correlation. Non-normally distributed traits were normal-
ised by log-transformation. For the association of gene
variants with fasting plasma glucose we calculated the
proportion that could be accounted for by association with
insulin release or insulin sensitivity by dividing the
expected effect with the observed effect. The expected
effect of gene variants on fasting plasma glucose, given the
association with insulin release (BIGTT-AIR) or insulin
sensitivity (BIGTT-SI), was calculated by multiplying the
single nucleotide polymorphism (SNP) effect on insulin
release by the epidemiological effect between insulin
release and fasting plasma glucose. This triangulation
approach has been described previously [28]. The propor-
tion of variance explained by genetic variants was assessed
Characteristics Inter99 participants
Full cohorta Non-diabetic individualsa
n 6,094 5,722
Men (n) 3,036 2,814
Women (n) 3,058 2,908
Age (years) 46±8 46±8
BMI (kg/m2) 26.3±4.6 26±4.4
Waist circumference (cm) 86.7±13 85.9±13
Fasting plasma glucose (mmol/l) 5.6±1.1 5.5±0.5
30 min plasma glucose (mmol/l) 8.7±1.9 8.6±1.7
120 min plasma glucose (mmol/l) 6.2±2.2 6.0±1.5
Fasting serum insulin (pmol/l) 35 (24–52) 34 (23–49)
30 min serum insulin (pmol/l) 246 (175–355) 246 (176–355)
120 min serum insulin (pmol/l) 157 (96–257) 153 (94–246)
HbA1c (%) 5.8 (5.6–6.1) 5.8 (5.5–6.1)
Corrected insulin response 92.9 (57–152) 96.1 (59.8–156)
BIGTT-AIR 1,630 (1,280–2,080) 1,640 (1,300–2,090)
HOMA-IR 1.21 (0.82–1.90) 1.16 (0.80–1.76)
BIGTT-SI 9.18±4.10 9.44±3.90
DI 1 14,800 (10,300–19,800) 15,200 (10,900–20,000)
DI 2 74.8 (41.6–137) 79.2 (44.9–141)
Table 1 Quantitative metabolic
traits in the population-based
Inter99 cohort
Data are median (25–75%
range) or mean±SD. DI 1 was
calculated as BIGTT-AIR×
BIGTT-SI; DI 2 was calculated
as CIR×1/HOMA-IR
aWith available DNA and glucose
tolerance determined
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by the partial R2 from a linear regression model including
main effects of all selected variants. Analyses were
performed using RGui, version 2.10.0 (www.r-project.org).
Statistical power Statistical power was calculated as
previously reported [25]. Depending on allele frequency
(range 11–49%), we had 80% statistical power at a 5%
significance level to detect an allele-dependent difference
of 5.3% to 8.4% of a standard deviation corresponding to
a 2.2% to 3.5% difference in BIGTT-AIR, a 3.8% to 6.0%
difference in CIR and an absolute 0.21 to 0.33 difference
in BIGTT-SI.
Results
We genotyped the following 11 variants in the Danish
population-based Inter99 cohort (Table 1): DGKB/
TMEM195 rs2191349, ADCY5 rs11708067, MADD
rs7944584, ADRA2A rs10885122, FADS1 rs174550, CRY2
rs11605924, SLC2A2 rs11920090, GLIS3 rs7034200,
PROX1 rs340874, C2CD4B rs11071657 and IGF1
rs35767. Results in Inter99 for traits reflecting fasting
glucose homeostasis (plasma glucose, serum insulin,
HOMA-IR and HOMA-B) have been previously reported
[18], but are presented for comparison in Table 2 and
Electronic supplementary materials (ESM) Table 1. Inter99
association results for six known fasting glucose loci have
been published previously [10, 12, 21–23]. In 5,722 non-
diabetic Inter99 participants we tested the above-named 11
variants for association with quantitative OGTT-based
estimates of beta cell function and insulin sensitivity
(Table 2). Carriers of the DGKB/TMEM195 rs2191349
glucose-raising T-allele showed decreased glucose-
stimulated insulin release as assessed by serum insulin at
30 min (2.7% [95% CI 0.6–4.7], p=0.01), BIGTT-AIR
(2.7% [1.1–4.2], p=0.0009) and CIR (2.8% [0.2–5.5%], p=
0.03; Table 2). Likewise, carriers of the glucose-raising G-
allele of ADRA2A rs10885122 showed a consistent de-
creased insulin response after oral glucose ingestion
evaluated by CIR (5.9% [1.8–10%], p=0.005), BIGTT-
AIR (3.5% [1.1–6.0%], p=0.005) and two different
disposition indices (DI 1 4.2% [1.2–7.1%], p=0.005, DI 2
9.3% [4.6–14%], p=0.0001; Table 2). Also, carriers of the
glucose-raising A-allele of C2CD4B rs11071657 had a
4.3% (1.6–7.0%, p=0.002) decreased insulin release as
assessed by the CIR index, consistent with a 3.2% (1.5–
4.8%, p=0.0002) decreased BIGTT-AIR index and a 3.1%
(1.1–5.0%, p=0.002) decreased DI (Table 2). Similarly,
carriers of the glucose-raising A-allele of GLIS3 rs7034200
had a decreased glucose-stimulated insulin release assessed
by BIGTT-AIR (3.1% [1.4–4.7%], p=0.0002). The CRY2
rs11605924 glucose-raising A-allele was associated with a
2.6 to 3.8% decrease in two different disposition indices
(p<0.02), while the diabetes-related PROX1 rs340874 C-
allele showed a 2.7% (0.6–4.8%, p=0.01) decreased serum
insulin at 30 min during OGTT and 2.9% decreased CIR
(0.3–5.5%, p=0.03). Also, association with a single
estimate of glucose-induced insulin response was observed
for MADD rs7944584 (DI 2 3.9% [0.4–7.4%], p=0.03),
FADS1 rs174550 (DI 1 −2.5% [−4.4 to −0.51%], p=0.01)
and SLC2A2 (CIR 4.3% [0.6–8.1%], p=0.02). Besides
association of the CRY2 variant (p=0.02), none of the
examined variants was associated with the BIGTT-SI
estimate of insulin sensitivity. All results were virtually
unchanged in models including BMI as an explanatory
variable or when analysing a subset of participants with
normal glucose tolerance (data not shown).
Given this complex pattern of association we determined
the pairwise correlation between the investigated OGTT-
derived traits and traits reflecting fasting glucose homeo-
stasis in all non-diabetic participants of Inter99 (ESM
Table 2). These analyses showed modest correlation between
various OGTT-based indices of glucose-stimulated insulin
release, accounting for some of the discrepancies in observed
associations.
The relationship between concomitant insulin sensitiv-
ity and insulin release from the pancreatic beta cell is
described by a hyperbola [29]. To illustrate the genotype-
related relationship between estimates of insulin sensitiv-
ity and insulin release, we plotted two-dimensional
standard error ellipses of the genotype-specific means of
BIGTT-SI and BIGTT-AIR (Fig. 1). Variants at DGKB/
TMEM195, ADRA2A, GLIS3 and C2CD4B loci showed a
distinct pattern consistent with a main effect on BIGTT-
AIR, whereas the two-dimensional impact of variants in
CRY2, PROX1 and FADS1 loci did not support an effect
on glucose-stimulated insulin release. In this bivariate
analysis the CRY2 variant was associated with BIGTT-
AIR and BIGTT-SI, underlining the association with the
BIGTT-SI estimate of insulin sensitivity in univariate
analysis (Table 2).
To assess the proportion of the association with fasting
plasma glucose (Table 2) that could be attributed to insulin
release or insulin sensitivity, we calculated the expected
effect size for association between a SNP and fasting
glucose given the SNP association with the BIGTT-AIR or
BIGTT-SI estimates of insulin release and sensitivity, and
the SNP-independent association between BIGTT-AIR or
BIGTT-SI and fasting glucose. We then compared the
expected effect with the observed effect on fasting glucose
to assess the proportion of association possibly mediated
by insulin release or sensitivity (ESM Table 3). These
calculations were done for the seven variants associated
with fasting plasma glucose in Inter99. For the four loci
strongly associated with insulin release in Inter99 (DGKB/
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TMEM195, ADRA2A, GLIS3 and C2CD4B), the proportion
of effect on fasting glucose that could be ascribed to
association with BIGTT-AIR ranged from 34% to 57%.
Also, the proportions of effect on fasting glucose at the
FADS1 and CRY2 loci that were explained by association
with insulin sensitivity (BIGTT-SI) were 39% and 48%,
respectively (ESM Table 3).
Discussion
Recent advances in the genetic exploration of traits related
to fasting glucose homeostasis have revealed 17 loci
associated with fasting plasma glucose or fasting serum
insulin [18], of which six known loci have been previously
reported [10, 12, 21–23]. In the current paper we aimed to
evaluate the impact of variants at the 11 novel loci on
OGTT-based insulin sensitivity and to estimate beta cell
function by analysis of a range of measures of glucose-
stimulated insulin release in non-diabetic middle-aged
individuals. The study demonstrates that of ten novel loci
associated with increased fasting plasma glucose at least
four (DGKB/TMEM195, ADRA2A, GLIS3 and C2CD4B),
and possibly one additional locus (PROX1), are associated
with reduced insulin response to oral glucose. These loci
thus join the growing list of common variants with a
modest effect on pancreatic beta cell function. We found
that the lead variants in or near DGKB/TMEM195,
ADRA2A, CRY2, GLIS3, PROX1 and C2CD4B were
associated with two or more of five correlated estimates
of insulin release, while variants in or near FADS1, SLC2A2
and MADD were associated with a single insulin release
measure. With the exception of probably sporadic associ-
ations with SLC2A2 and MADD, all effects showed a
decrease in glucose-stimulated insulin release in carriers of
the allele that also increased fasting glucose in the previous
combined report [18]. However, two-dimensional plots of
insulin sensitivity in relation to insulin release did not
support the impact of CRY2 and FADS1 variants on
glucose-stimulated insulin release. In line with univariate
analysis, two-dimensional data for CRY2 pointed to a
possible impact on insulin sensitivity. Yet, the MAGIC
study did not show an effect on HOMA-IR in more than
35,000 individuals, underlining the uncertainty of the
present association [18].
The IGF1 variant previously associated with increased
fasting insulin levels and increased HOMA-IR did not
associate with an OGTT-based insulin SI in the present
study, highlighting the difficulties in establishing genetic
variants that influence insulin sensitivity. Besides lack of
statistical power, these difficulties could be explained by
the relatively poor phenotypic estimation of insulin resis-
tance in most datasets. Also, insulin resistance variants are
probably more prone to interaction with correlated pheno-
types or environmental factors, such as obesity, physical
activity or dietary intake, thus obscuring association and
replication in studies of genetic main effects [6].
Association of DGKB/TMEM195, ADRA2A, GLIS3,
PROX1 and C2CD4B loci with glucose-stimulated insulin
release is consistent with genes in these loci being
expressed in the pancreas and human islet cells [18].
However, the more exact molecular mechanisms of action
Fig. 1 Two-dimensional SEM of BIGTT-SI and logarithm of BIGTT-
AIR stratified according to the genotype of (a) DGKB/TMEM195
rs2191349, (b) ADRA2A rs10885122, (c) FADS1 rs174550, (d) CRY2
rs11605924, (e) GLIS3 rs7034200, (f) PROX1 rs340874 and (g)
C2CD4B rs11071657 in 5,722 non-diabetic participants of the Inter99
cohort. SE ellipses around the mean of each genotype level were
constructed assuming bivariate normal distribution. The multivariate
method, Hotelling T2, was applied to test the simultaneous effect of
genotype on the two traits of insulin release and insulin sensitivity
assuming an additive model with age as a covariate. Continuous line,
SE for homozygous reference allele carriers; dashed line, SE for
heterozygous carriers; dotted line, SE for homozygous glucose-raising
allele carriers. a p=0.005; (b) p=0.001; (c) p=0.2; (d) p=0.03; (e) p=
0.002; (f) p=0.2; (g) p=5×10−4
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cannot be inferred from the current data. Interestingly,
DGKB/TMEM195 rs2191341 and PROX1 rs340874 were
associated with type 2 diabetes at genome-wide signifi-
cance (p<5×10−8) in the MAGIC publication, while the
other three variants showing an effect on pancreatic beta
cell function had limited impact on risk of type 2 diabetes
in data from the MAGIC investigators (OR 1.03–1.04, p=
0.001–0.02) [18]. In addition, when comparing the effect on
insulin release of variants associated with type 2 diabetes in
the MAGIC publication [18] with that of variants not
associated with type 2 diabetes, we observed no clear
distinction between these groups. Given these observations,
there is no clear correlation between genetically impaired
beta cell function in the general population and risk of type 2
diabetes. However, it is possible that lack of statistical power
to obtain high confidence in association for these low-impact
variants may have obscured the genuine coherence.
Our novel findings of glucose-stimulated insulin release
are largely in agreement with the MAGIC paper [18], in
which four of the ten fasting glucose variants examined
here were also associated at genome-wide significance with
basal beta cell function under non-stimulated conditions as
estimated from the HOMA-B model. In our study of large-
scale genetic physiology, we applied OGTT to estimate the
glucose-stimulated insulin response, a method that is
superior to the HOMA-B model in providing a reliable
surrogate measure of first-phase insulin release [19, 27]. Yet
the correlation between different OGTT-based estimates of
insulin release was not complete, as shown by results in
ESM Table 2. Interestingly, HOMA-B correlated strongly
with HOMA-IR and fasting serum insulin, and modestly
with the CIR and BIGTT-AIR estimates of insulin release
in Inter99. Therefore it is essential to investigate stimulated
insulin release in order to substantiate a beta cell dysfunc-
tion as the pathogenic mechanism potentially leading to
increased fasting glucose and type 2 diabetes. The
importance of this statement is stressed by the observation
that ADRA2A rs10885122 was not associated with HOMA-
B at genome-wide significance in the MAGIC paper and
did not replicate strongly (p=0.03) in ∼60,000 individuals
[18]; yet the current data provide strong evidence of a
postprandial insulin release defect. The functional and
genetic impact of ADRA2A on dynamic insulin secretion
was also described in a recent paper showing reduced in
vitro insulin secretion and impaired docking of insulin
granule in carriers of variants in ADRA2A [30]. Despite the
application of OGTT-based estimates of beta cell function,
we cannot rule out the possibility that the lack of consistent
association with beta cell function for variants at ADCY5,
MADD, FADS1, CRY2 and SLC2A2 in the present study is
due to lack of statistical power. Interestingly, in up to
61,907 replication samples of the MAGIC study [18],
variants in MADD, CRY2 and SLC2A2 that had otherwise
been associated with HOMA-B did not convincingly
replicate, a finding supported by the current data, which
question the effect of these variants on pancreatic beta cell
function. Also, the lack of consistent association of the
ADCY5 variant with orally stimulated insulin release in the
present report is in accordance with results of another report
by the MAGIC investigators involving ∼19,000 OGTT-
investigated individuals who were tested for the highly
correlated (r2=0.85) rs2877716 variant [31].
In Inter99 we had 80% statistical power to detect an effect
size of 0.05 to 0.08 SD depending on allele frequency. For
comparison, the effect on fasting plasma glucose in Inter99
ranged from 0 SD (C2CD4B) to 0.07 SD (ADRA2A),
indicating that the Inter99 cohort is marginally underpowered
to detect such low impacts. Also, we acknowledge that the
present report applies a liberal statistical significance
threshold. Performing conservative Bonferroni correction
for 11 gene variants implies a corrected alpha of 0.0045,
leaving associations between glucose-stimulated insulin
response and variants at DGKB/TMEM195, ADRA2A, GLIS3
and C2CD4B loci significant at this threshold.
Interestingly, from a genetic viewpoint the major impact
on risk of type 2 diabetes and fasting hyperglycaemia is
through decreased function of the pancreatic beta cell. In
triangulation analyses we estimated that for the four
variants with an impact on beta cell function, around 30%
to 60% of the effect on fasting plasma glucose could be
accounted for by association with glucose-stimulated
insulin release. These estimates suggest the existence of
additional glucose-raising mechanisms that are independent
of glucose-stimulated insulin release. Despite the high
number of statistically highly associated variants discovered
in the last few years, the explained proportion of the inter-
individual variation reported in Inter99 for the combination
of all 33 validated type 2 diabetes and/or fasting plasma
glucose gene variants is only 5.8% for fasting plasma
glucose and 4.2% to 5.7% for different estimates of
glucose-stimulated insulin release in non-diabetic Danish
people (data not shown). These numbers should be
interpreted in relation to heritability estimates of 30% to
40% and 60% to 80% for fasting glucose and first-phase
insulin release, respectively [32], indicating that 15% to
20% and 5% to 10%, respectively, of the genetic contribu-
tion to these traits has been accounted for. These estimates
imply that a major part of the genetic contribution to these
quantitative traits is yet to be unravelled.
In conclusion, in a large OGTT-investigated population-
based cohort we found that the lead variants at the DGKB/
TMEM195, ADRA2A, GLIS3 and C2CD4B loci were
associated with decreased glucose-stimulated insulin re-
sponse, underlining the importance of pancreatic beta cell
dysfunction in genetic predisposition to hyperglycaemia
and type 2 diabetes.
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